ESAIY
Eisai Co., Ltd.
Set alert
7.95 USD +0.10 +1.27%
7.95 Day range 7.97
5.69 52-week range 8.58
- YTD
- +7.72%
- 1 year
- +8.90%
- Open
- 7.97
- Prev close
- 7.85
- Mkt cap
- 8.98B
- Vol
- 2.84K
- Avg vol
- 59.50K
- EPS
- 0.23
- P/E
- 34.57
More statistics
- Low
- 7.95
- High
- 7.97
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2026 | Mar 31, 2026 | — | -0.0184 | — | — |
| Feb 4, 2026 | Dec 31, 2025 | — | 0.09889 | — | — |
| Nov 5, 2025 | Sep 30, 2025 | — | 0.06102 | — | — |
| Jul 30, 2025 | Jun 30, 2025 | 0.05949 | 0.08996 | +0.03 | +51.22% |
| May 12, 2025 | Mar 31, 2025 | — | 0.00536 | — | — |
| Feb 3, 2025 | Dec 31, 2024 | — | 0.00088 | — | — |
News
- Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
- FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
- Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
- Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
- Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
- These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
- Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
- Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
- Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
- Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
Your note
Sign in to keep a note on ESAIY — it syncs with the Stock Master app.